Drug Trial Radar · NCT05680558
Photopheresis in Early-stage Mycosis Fungoides
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
74
Planned (sponsor's estimate)
Start
May 8, 2021
Primary completion
Mar 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mallinckrodt
- First posted
- Jan 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a clinical response.
Conditions
- Cutaneous T Cell Lymphoma
- Mycosis Fungoides
Interventions
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX PhotopheresisDrug
Extracorporeal Photopheresis (ECP)
THERAKOS® CELLEX photopheresis systemDevice
THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: 1 Year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.